Related Experiment Video
Updated: Apr 24, 2026
07:04
Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
18.8K
Sodium Glucose-Like Co-Transporter 2 Inhibitor (SGLT2i) Use in Adults With Cystic Fibrosis
Ellie Johnson1, Angela Matson1,2, Robyn Cobb1,3
1The Prince Charles Hospital, Adult Cystic Fibrosis Centre Brisbane Australia.
Respirology Case Reports
|April 23, 2026
Summary
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) show promise for managing diabetes and kidney issues in cystic fibrosis (CF) patients. These SGLT2 inhibitors were well-tolerated and effective in three adults with CF, offering new therapeutic options.
Area of Science:
- Endocrinology
- Nephrology
- Metabolic Disorders
Background:
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i) offer multi-system benefits, but their use in cystic fibrosis (CF) is not well-documented.
- An aging CF population and advancements in CF treatment necessitate exploring new therapeutic avenues.
Purpose of the Study:
- To describe the safe, tolerable, and effective use of SGLT2i in adults with CF.
- To add to the limited evidence regarding SGLT2i in people with CF (pwCF).
Main Methods:
- Case series describing the use of SGLT2i in three adult patients with CF.
- Indications included glycaemic management for type 2 diabetes, CF diabetes-related nephropathy, and non-diabetes related nephropathy.
Main Results:
- All three patients tolerated SGLT2i without any reported side effects.
- SGLT2i demonstrated effectiveness in managing diverse conditions in the studied CF population.
Conclusions:
- SGLT2i can be safely, tolerably, and effectively used in adults with CF.
- Findings support the expanded use of SGLT2i in pwCF, particularly in the context of an aging population and post-modulator era.
Related Concept Videos
01:55Secondary Active Transport
122.7K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
122.7K
01:32Secondary Active Transport
12.7K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
12.7K
01:27Glucose Transporters
15.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
15.1K
01:26Glucose Absorption Into the Small Intestine
33.9K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
33.9K
01:24Cystic Fibrosis: Management
649
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
649
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
945
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
945